Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 209

Results For "PLI"

3349 News Found

Nureca's subsidiary receives ISO 13485 certification for Indian medical device facility
Medical Device | October 09, 2022

Nureca's subsidiary receives ISO 13485 certification for Indian medical device facility

The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries


Thermo Fisher Scientific emphasizes on the need for more disruptive technologies
Medical Device | October 09, 2022

Thermo Fisher Scientific emphasizes on the need for more disruptive technologies

Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.


Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
Drug Approval | October 07, 2022

Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets

Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.


Atul Healthcare to acquire stake in VIMS
News | October 05, 2022

Atul Healthcare to acquire stake in VIMS

The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital


NATCO launches Chlorantraniliprole combination agro products in India
News | October 05, 2022

NATCO launches Chlorantraniliprole combination agro products in India

Both products are broad-spectrum, foliar insecticides used across wide range of crops


Lupin receives approval from USFDA for Darunavir Tablets
Drug Approval | October 05, 2022

Lupin receives approval from USFDA for Darunavir Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.


Casper Pharma receives EIR from USFDA for its PAI
Drug Approval | October 05, 2022

Casper Pharma receives EIR from USFDA for its PAI

The inspection concluded with no observation (FDA-483) issued.


Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets
Drug Approval | October 04, 2022

Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency


Lupin gets EIR from USFDA for its Ankleshwar facility
Drug Approval | October 03, 2022

Lupin gets EIR from USFDA for its Ankleshwar facility

The inspection of the facility was conducted from August 16-19, 2022.